Fig. 1From: Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a caseChest CT scan (a): during the episode of acute respiratory failure after 5 months of treatment with trametinib, (b): 7 months after trametinib discontinuation and 5 months after vemurafenib initiation, (c): 15 months after vemurafenib initiation, (d): 6 months after vemurafenib discontinuationBack to article page